Notably, the FDA has already granted accelerated approval to Venclexta in combination with Vidaza or decitabine or low-dose cytarabine for the treatment of newly diagnosed AML in patients aged 75 years or older or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions.Results of the phase I NP30179 study showed durable complete responses with glofitamab in patients with aggressive and indolent lymphomas after a median of three prior lines of therapy.